Financing, Pharma

Ophthotech in $85 million IPO financing

Posted on 19 August 2013

Tags: , , ,

Ophthotech has entered into an IPO financing round in the hope of raising up to $85 million.

After assembling a whopping $175 million financing deal this spring, Ophthotech has filed paperwork with the SEC to secure up to $85 million more in an IPO financing round.

Ophthotech has hit the IPO financing trail after announcing plans to advance its lead therapy Fovista into Phase III clinical development for wet age-related macular degeneration by the end of 2013.

Upbeat results from a Phase IIb study showed that a treatment with a combination of the compound, an inhibitor of platelet-derived growth factor, and Roche's anti-VEGF therapy Lucentis, outperformed Lucentis alone for treating the leading cause of blindness in people aged 55 and older.


View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply